Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

L D Loomis-Price

Showing results (11-20 of 15) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 15 results.
AIDS Research and Human Retroviruses|February 15, 2001
HIV type 1 subtype E-infected patients with broadened, dual (B/E) V3 loop serology have increased cross-neutralizing antibodiesV R Polonis, M S De Souza, P Chanbancherd, et al.
AIDS Research and Human Retroviruses|December 31, 1998
HIV type 1 subtypes in Malaysia, determined with serologic assays: 1992-1996C Beyrer, T C Vancott, N K Peng, et al.
The Journal of Infectious Diseases|October 21, 1998
Correlation between humoral responses to human immunodeficiency virus type 1 envelope and disease progression in early-stage infectionL D Loomis-Price, J H Cox, J R Mascola, et al.
The Journal of Infectious Diseases|August 7, 1999
Preliminary evaluation of human immunodeficiency virus type 1 (HIV-1) immunogen in children with HIV-1 infectionS Sei, S L Sandelli, G Theofan, et al.
The Journal of Infectious Diseases|March 18, 2000
Efficacy testing of recombinant human immunodeficiency virus (HIV) gp160 as a therapeutic vaccine in early-stage HIV-1-infected volunteers. rgp160 Phase II Vaccine InvestigatorsD L Birx, L D Loomis-Price, N Aronson, et al.
Pageof 2

Showing results (11-20 of 15) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 15 results.
AIDS Research and Human Retroviruses|February 15, 2001
HIV type 1 subtype E-infected patients with broadened, dual (B/E) V3 loop serology have increased cross-neutralizing antibodiesV R Polonis, M S De Souza, P Chanbancherd, et al.
AIDS Research and Human Retroviruses|December 31, 1998
HIV type 1 subtypes in Malaysia, determined with serologic assays: 1992-1996C Beyrer, T C Vancott, N K Peng, et al.
The Journal of Infectious Diseases|October 21, 1998
Correlation between humoral responses to human immunodeficiency virus type 1 envelope and disease progression in early-stage infectionL D Loomis-Price, J H Cox, J R Mascola, et al.
The Journal of Infectious Diseases|August 7, 1999
Preliminary evaluation of human immunodeficiency virus type 1 (HIV-1) immunogen in children with HIV-1 infectionS Sei, S L Sandelli, G Theofan, et al.
The Journal of Infectious Diseases|March 18, 2000
Efficacy testing of recombinant human immunodeficiency virus (HIV) gp160 as a therapeutic vaccine in early-stage HIV-1-infected volunteers. rgp160 Phase II Vaccine InvestigatorsD L Birx, L D Loomis-Price, N Aronson, et al.
Pageof 2